These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 28533311)

  • 1. Converting Lymphoma Cells into Potent Antigen-Presenting Cells for Interferon-Induced Tumor Regression.
    Liao J; Luan Y; Ren Z; Liu X; Xue D; Xu H; Sun Z; Yang K; Peng H; Fu YX
    Cancer Immunol Res; 2017 Jul; 5(7):560-570. PubMed ID: 28533311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overcoming rituximab drug-resistance by the genetically engineered anti-CD20-hIFN-α fusion protein: Direct cytotoxicity and synergy with chemotherapy.
    Vega GG; Franco-Cea LA; Huerta-Yepez S; Mayani H; Morrison SL; Bonavida B; Vega MI
    Int J Oncol; 2015 Nov; 47(5):1735-48. PubMed ID: 26398317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma.
    Xuan C; Steward KK; Timmerman JM; Morrison SL
    Blood; 2010 Apr; 115(14):2864-71. PubMed ID: 20139095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical study of Ublituximab, a Glycoengineered anti-human CD20 antibody, in murine models of primary cerebral and intraocular B-cell lymphomas.
    Ben Abdelwahed R; Donnou S; Ouakrim H; Crozet L; Cosette J; Jacquet A; Tourais I; Fournès B; Gillard Bocquet M; Miloudi A; Touitou V; Daussy C; Naud MC; Fridman WH; Sautès-Fridman C; Urbain R; Fisson S
    Invest Ophthalmol Vis Sci; 2013 May; 54(5):3657-65. PubMed ID: 23611989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CTLA-4 Limits Anti-CD20-Mediated Tumor Regression.
    Ren Z; Guo J; Liao J; Luan Y; Liu Z; Sun Z; Liu X; Liang Y; Peng H; Fu YX
    Clin Cancer Res; 2017 Jan; 23(1):193-203. PubMed ID: 27354469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD8+ T-cell-dependent immunity following xenogeneic DNA immunization against CD20 in a tumor challenge model of B-cell lymphoma.
    Palomba ML; Roberts WK; Dao T; Manukian G; Guevara-Patiño JA; Wolchok JD; Scheinberg DA; Houghton AN
    Clin Cancer Res; 2005 Jan; 11(1):370-9. PubMed ID: 15671568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-CD20-interferon-β fusion protein therapy of murine B-cell lymphomas.
    Trinh KR; Vasuthasawat A; Steward KK; Yamada RE; Timmerman JM; Morrison SL
    J Immunother; 2013 Jun; 36(5):305-18. PubMed ID: 23719241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab.
    Rufener GA; Press OW; Olsen P; Lee SY; Jensen MC; Gopal AK; Pender B; Budde LE; Rossow JK; Green DJ; Maloney DG; Riddell SR; Till BG
    Cancer Immunol Res; 2016 Jun; 4(6):509-19. PubMed ID: 27197068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Human/mouse chimeric anti-CD20 monoclonal antibody enhances antigen presentation in dendritic cells and induces anti-lymphoma CTL effects].
    Ai LM; Ren HY; Shi YJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Dec; 15(6):1247-52. PubMed ID: 18088477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD20 alternative splicing isoform generates immunogenic CD4 helper T epitopes.
    Vauchy C; Gamonet C; Ferrand C; Daguindau E; Galaine J; Beziaud L; Chauchet A; Henry Dunand CJ; Deschamps M; Rohrlich PS; Borg C; Adotevi O; Godet Y
    Int J Cancer; 2015 Jul; 137(1):116-26. PubMed ID: 25449106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vinorelbine, cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma.
    Orecchioni S; Talarico G; Labanca V; Calleri A; Mancuso P; Bertolini F
    Br J Cancer; 2018 May; 118(10):1329-1336. PubMed ID: 29695766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
    Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
    Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting IFNα to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance.
    Liang Y; Tang H; Guo J; Qiu X; Yang Z; Ren Z; Sun Z; Bian Y; Xu L; Xu H; Shen J; Han Y; Dong H; Peng H; Fu YX
    Nat Commun; 2018 Nov; 9(1):4586. PubMed ID: 30389912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells.
    Zah E; Lin MY; Silva-Benedict A; Jensen MC; Chen YY
    Cancer Immunol Res; 2016 Jun; 4(6):498-508. PubMed ID: 27059623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti-CD20 x anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels.
    Stanglmaier M; Faltin M; Ruf P; Bodenhausen A; Schröder P; Lindhofer H
    Int J Cancer; 2008 Sep; 123(5):1181-9. PubMed ID: 18546289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of Rituximab-resistant B-cell lymphoma with a novel multi-component anti-CD20 mAb nanocluster.
    Li H; Zhang G; Jiang C; Zhang F; Ke C; Zhao H; Sun Y; Zhao M; Chen D; Zhu X; Zhang L; Li B; Dai J; Li W
    Oncotarget; 2015 Sep; 6(27):24192-204. PubMed ID: 26284588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A bispecific antibody-IFNalpha2b immunocytokine targeting CD20 and HLA-DR is highly toxic to human lymphoma and multiple myeloma cells.
    Rossi EA; Rossi DL; Stein R; Goldenberg DM; Chang CH
    Cancer Res; 2010 Oct; 70(19):7600-9. PubMed ID: 20876805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.
    Vilain RE; Menzies AM; Wilmott JS; Kakavand H; Madore J; Guminski A; Liniker E; Kong BY; Cooper AJ; Howle JR; Saw RPM; Jakrot V; Lo S; Thompson JF; Carlino MS; Kefford RF; Long GV; Scolyer RA
    Clin Cancer Res; 2017 Sep; 23(17):5024-5033. PubMed ID: 28512174
    [No Abstract]   [Full Text] [Related]  

  • 19. Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy.
    Wang X; Schoenhals JE; Li A; Valdecanas DR; Ye H; Zang F; Tang C; Tang M; Liu CG; Liu X; Krishnan S; Allison JP; Sharma P; Hwu P; Komaki R; Overwijk WW; Gomez DR; Chang JY; Hahn SM; Cortez MA; Welsh JW
    Cancer Res; 2017 Feb; 77(4):839-850. PubMed ID: 27821490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transfer of Allogeneic CD4+ T Cells Rescues CD8+ T Cells in Anti-PD-L1-Resistant Tumors Leading to Tumor Eradication.
    Arina A; Karrison T; Galka E; Schreiber K; Weichselbaum RR; Schreiber H
    Cancer Immunol Res; 2017 Feb; 5(2):127-136. PubMed ID: 28077434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.